Lactobacillus paracasei strain
US-12152232-B2 · Nov 26, 2024 · US
US9962415B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9962415-B2 |
| Application number | US-201414787817-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 1, 2014 |
| Priority date | May 3, 2013 |
| Publication date | May 8, 2018 |
| Grant date | May 8, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.
Opening claim text (preview).
The invention claimed is: 1. A method for promoting weight loss or preventing weight gain in an obese or overweight subject having low responsiveness to a calorie restricted diet, the low responsiveness dependent on gut microbiota composition of the obese or overweight subject, the gut microbiota composition of the obese or overweight subject who has low responsiveness to the calorie restricted diet comprises a higher proportion of Lachnospiraceae relative to that of a normal weight subject, the method comprising the step of administering an agent comprising a probiotic comprising Lactobacillus rhamnosus CGMCC 1.3724 to the subject. 2. The method according to claim 1 , wherein the agent is administered during, subsequent to and/or prior to the calorie restricted diet, in an amount therapeutically effective for promoting weight loss in the obese or overweight subject having low responsiveness to the calorie restricted diet. 3. The method according to claim 1 , wherein the agent is administered subsequent to the calorie restricted diet, in an amount therapeutically effective for preventing weight gain in the obese or overweight subject having low responsiveness to the calorie restricted diet. 4. The method according to claim 1 , wherein the calorie restricted diet is a dietary regimen for at least twelve weeks, and the agent is administered during the calorie restricted diet and also during a subsequent period without calorie restriction for at least twelve additional weeks. 5. The method according to claim 1 , wherein the weight loss involves a body fat loss, or the weight gain involves a body fat gain. 6. The method according to claim 1 , wherein the Lactobacillus rhamnosus CGMCC 1.3724 is administered to the subject at a daily dosage in the range of 10 2 to 10 12 cfu. 7. The method according to claim 1 , wherein the agent is administered to the subject during, subsequent to and/or prior to the calorie restricted diet, the calorie restricted diet involves a reduction of the daily calorie intake in the range of 200 to 1000 kcal. 8. The method according to claim 1 , wherein the proportion of Lachnospiraceae in the gut microbiota composition of the obese or overweight subject who has the low responsiveness to the calorie restricted diet exceeds that of a normal weight subject by at least 5%. 9. The method according to claim 1 , wherein the proportion of Lachnospiraceae in the gut microbiota composition of the obese or overweight subject who has the low responsiveness to the calorie restricted diet exceeds that of a normal weight subject by at least 10%. 10. The method according to claim 1 , wherein the proportion of Lachnospiraceae in the gut microbiota composition of the obese or overweight subject who has the low responsiveness to the calorie restricted diet exceeds that of a normal weight subject by at least 15%. 11. The method according to claim 1 , wherein the agent is administered to the subject for a period of time of greater than 12 weeks.
Anorexiants; Antiobesity agents · CPC title
from microorganisms other than algae or fungi, e.g. protozoa or bacteria · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title
Quantitative determination · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.